BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 26950369)

  • 1. Structure and ligand-binding mechanism of the human OX1 and OX2 orexin receptors.
    Yin J; Babaoglu K; Brautigam CA; Clark L; Shao Z; Scheuermann TH; Harrell CM; Gotter AL; Roecker AJ; Winrow CJ; Renger JJ; Coleman PJ; Rosenbaum DM
    Nat Struct Mol Biol; 2016 Apr; 23(4):293-9. PubMed ID: 26950369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant.
    Yin J; Mobarec JC; Kolb P; Rosenbaum DM
    Nature; 2015 Mar; 519(7542):247-50. PubMed ID: 25533960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based development of a subtype-selective orexin 1 receptor antagonist.
    Hellmann J; Drabek M; Yin J; Gunera J; Pröll T; Kraus F; Langmead CJ; Hübner H; Weikert D; Kolb P; Rosenbaum DM; Gmeiner P
    Proc Natl Acad Sci U S A; 2020 Jul; 117(30):18059-18067. PubMed ID: 32669442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystal Structures of Human Orexin 2 Receptor Bound to the Subtype-Selective Antagonist EMPA.
    Suno R; Kimura KT; Nakane T; Yamashita K; Wang J; Fujiwara T; Yamanaka Y; Im D; Horita S; Tsujimoto H; Tawaramoto MS; Hirokawa T; Nango E; Tono K; Kameshima T; Hatsui T; Joti Y; Yabashi M; Shimamoto K; Yamamoto M; Rosenbaum DM; Iwata S; Shimamura T; Kobayashi T
    Structure; 2018 Jan; 26(1):7-19.e5. PubMed ID: 29225076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Human Orexin/Hypocretin Receptor Crystal Structures.
    Yin J; Rosenbaum DM
    Curr Top Behav Neurosci; 2017; 33():1-15. PubMed ID: 28025809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping the binding pocket of dual antagonist almorexant to human orexin 1 and orexin 2 receptors: comparison with the selective OX1 antagonist SB-674042 and the selective OX2 antagonist N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethyl-acetamide (EMPA).
    Malherbe P; Roche O; Marcuz A; Kratzeisen C; Wettstein JG; Bissantz C
    Mol Pharmacol; 2010 Jul; 78(1):81-93. PubMed ID: 20404073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Suvorexant, a Dual Orexin/Hypocretin Receptor Antagonist, on Impulsive Behavior Associated with Cocaine.
    Gentile TA; Simmons SJ; Watson MN; Connelly KL; Brailoiu E; Zhang Y; Muschamp JW
    Neuropsychopharmacology; 2018 Apr; 43(5):1001-1009. PubMed ID: 28741623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis.
    Rappas M; Ali AAE; Bennett KA; Brown JD; Bucknell SJ; Congreve M; Cooke RM; Cseke G; de Graaf C; Doré AS; Errey JC; Jazayeri A; Marshall FH; Mason JS; Mould R; Patel JC; Tehan BG; Weir M; Christopher JA
    J Med Chem; 2020 Feb; 63(4):1528-1543. PubMed ID: 31860301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure-Activity Relationships, and Sleep-Promoting Properties in Rats.
    Brotschi C; Roch C; Gatfield J; Treiber A; Williams JT; Sifferlen T; Heidmann B; Jenck F; Bolli MH; Boss C
    ChemMedChem; 2019 Jul; 14(13):1257-1270. PubMed ID: 31066976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of Orexin Receptor Binding and Activation-A Molecular Dynamics Study.
    Karhu L; Magarkar A; Bunker A; Xhaard H
    J Phys Chem B; 2019 Mar; 123(12):2609-2622. PubMed ID: 30786708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
    Hoyer D; Jacobson LH
    Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of human Orexin-1 and -2 G-protein-coupled receptors with novel and published antagonists by modeling, molecular dynamics simulations, and site-directed mutagenesis.
    Heifetz A; Morris GB; Biggin PC; Barker O; Fryatt T; Bentley J; Hallett D; Manikowski D; Pal S; Reifegerste R; Slack M; Law R
    Biochemistry; 2012 Apr; 51(15):3178-97. PubMed ID: 22448975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of action of suvorexant.
    Stahl SM
    CNS Spectr; 2016 Jun; 21(3):215-8. PubMed ID: 27322687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
    Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist.
    Winrow CJ; Gotter AL; Cox CD; Doran SM; Tannenbaum PL; Breslin MJ; Garson SL; Fox SV; Harrell CM; Stevens J; Reiss DR; Cui D; Coleman PJ; Renger JJ
    J Neurogenet; 2011 Mar; 25(1-2):52-61. PubMed ID: 21473737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists.
    Malherbe P; Borroni E; Pinard E; Wettstein JG; Knoflach F
    Mol Pharmacol; 2009 Sep; 76(3):618-31. PubMed ID: 19542319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders.
    Boss C; Gatfield J; Brotschi C; Heidmann B; Sifferlen T; von Raumer M; Schmidt G; Williams JT; Treiber A; Roch C
    ChemMedChem; 2020 Dec; 15(23):2286-2305. PubMed ID: 32937014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of 1-substitution on tetrahydroisoquinolines as selective antagonists for the orexin-1 receptor.
    Perrey DA; German NA; Decker AM; Thorn D; Li JX; Gilmour BP; Thomas BF; Harris DL; Runyon SP; Zhang Y
    ACS Chem Neurosci; 2015 Apr; 6(4):599-614. PubMed ID: 25643283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Highly Potent Dual Orexin Receptor Antagonists via a Scaffold-Hopping Approach.
    Heidmann B; Gatfield J; Roch C; Treiber A; Tortoioli S; Brotschi C; Williams JT; Bolli MH; Abele S; Sifferlen T; Jenck F; Boss C
    ChemMedChem; 2016 Oct; 11(19):2132-2146. PubMed ID: 27390287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of methamphetamine on actigraphy-based sleep parameters in female rhesus monkeys: Orexin receptor mechanisms.
    Borgatti DA; Rowlett JK; Berro LF
    Drug Alcohol Depend; 2024 Jun; 259():111285. PubMed ID: 38636173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.